# Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

> **NCT02717884** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Michael Luebbert** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** tranylcypromine
- **DRUG:** all-trans retinoic acid
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT02717884
- **Lead sponsor:** Michael Luebbert
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717884, "Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02717884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*